ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sandoz signs biologics deal with Momenta

July 31, 2006 | APPEARED IN VOLUME 84, ISSUE 31

Novartis' Sandoz generic drug arm and Momenta Pharmaceuticals have formed a pact to develop follow-on versions of four existing biotechnology products. Sandoz has taken a $75 million stake in Momenta and will make milestone payments to the biotech firm of up to $188 million if all four drugs are commercialized. The collaboration expands into Europe the companies' U.S. partnership for M-Enoxaparin, a generic version of Sanofi-Aventis' Lovenox, a low-molecular-weight heparin for deep-vein thrombosis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment